Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 22,355 Shares

Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 22,355 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.65, for a total transaction of $171,015.75. Following the sale, the general counsel now directly owns 175,496 shares of the company’s stock, valued at $1,342,544.40. The trade was a 11.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pulmonx Trading Up 0.5 %

NASDAQ LUNG opened at $7.48 on Friday. The company has a fifty day simple moving average of $6.95 and a two-hundred day simple moving average of $6.94. The stock has a market cap of $297.67 million, a P/E ratio of -5.19 and a beta of 0.50. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $10.01. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The business had revenue of $23.77 million during the quarter, compared to analysts’ expectations of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Citigroup reissued a “neutral” rating and set a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Wells Fargo & Company decreased their target price on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Pulmonx has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LUNG. 272 Capital LP acquired a new stake in shares of Pulmonx in the third quarter worth $25,000. BNP Paribas Financial Markets acquired a new stake in shares of Pulmonx in the fourth quarter worth $43,000. R Squared Ltd acquired a new stake in shares of Pulmonx in the fourth quarter worth $46,000. ProShare Advisors LLC acquired a new stake in shares of Pulmonx in the fourth quarter worth $72,000. Finally, Stifel Financial Corp acquired a new stake in shares of Pulmonx in the fourth quarter worth $81,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.